Endocrine Abstracts

A 43-year-old roman, previously living in France was referred to the endocrinology department for Hashimoto’s hypothyroidism in 2017. Thyroid function was easily normalized by a treatment by thyroxine. She had also a medical history of severe alopecia since the age of 20. The diagnosis of androgenetic alopecia was made at that time by a French dermatologist and treatment by estradiol valerate 2 mg with cyproterone acetate (CPA) 50 mg was started. The dose of CPA was lower...

Objectives: In normal subjects, inhibitory effect of a glucose load (OGTT) on GH secretion is probably mediated by an increase in hypothalamic release of somatostatin whereas the stimulatory effect of arginine on GH secretion is probably mediated by a decrease in somatostatin release. In humans and animals, somatostatin infusion inhibits basal and TRH-stimulated TSH secretion but little is known on the role of endogenous somatostatin in the regulation of TSH secretion. The aim...

Introduction: Hyperparathyroidism (HPT) during pregnancy is rare but requires a specific approach for its diagnosis HPT is associated with a high incidence of associated maternal, fetal and neonatal complications, including miscarriage (3,5x-fold higher than expected), IUGR, prematurity and pre-eclampsia(1,2,3). The severity of complications is proportional to degree of maternal calcium level.Case report: We report the c...

Aim of the work: The effects of subclinical hyperthyroidism (SCH) on bone and heart have been well documented. Effects on other parameters like lipids metabolism and weight regulation have also been reported but mainly in cross-sectional studies. The potential benefits of treatment of endogenous subclinical hyperthyroidism are more controversial as few large controlled studies on clinical outcomes have been performed. ATA guidelines recommend treatment according to the severit...

Two nationwide surveys on acromegaly (AcroBel-1 and 2) have been performed in Belgium at an interval of five years, including centralized GH and IGF1 measurements in most patients. A normal IGF1 for age was observed in 56% of 311 vs 74% of 365 treated patients, in 2004 and 2009 respectively.Factors responsible for this improvement were investigated. A selection bias was unlikely as the follow-up rate was higher in patients with active (83%) or medically ...

Introduction: Recombinant human parathyroid hormone (rPTH) (1–34) is prescribed off-label in France for patients with hypoparathyroidism resistant to conventional therapy. However, the bone impact of this long-term replacement therapy is not well known.Objective: To determine the skeletal impact of chronic treatment with rPTH (1–34) in patients with hypoparathyroidism.Design: Single-center prospective study. Patients trea...